Is BioCryst Pharmaceuticals, Inc. overvalued?

BioCryst Pharmaceuticals, Inc. (BCRX) — key valuation metrics and fundamentals.

No verdict

Price

$7.61

Fair value

—

Current P/E

—

Normal P/E

—

Market cap

$1.96B

Dividend yield

0.0%

Return on equity

94.4%

Sector

Healthcare

Fair value compares BCRX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.

Related stocks